Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury

Atherosclerosis

Volumn 217, Issue 2, 2011, Pages 536-542

  Cai, Xue Ying ^a   Lu, Lin ^a   Wang, Ya Nan ^a   Jin, Cao ^a   Zhang, Rui Yan ^a   Zhang, Qi ^a   Chen, Qiu Jing ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute coronary syndrome; Receptor for advanced glycation end products; S100A6; S100B; S100P

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CALCYCLIN; PROTEIN S100B; S100P PROTEIN; TROPONIN I; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE INJURY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; STABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT; RISK FACTORS; S100 PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 79960699904     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.023     Document Type: Article

References (38)

1. Yan S.F., Ramasamy R., Schmidt A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009, 87:235-247.
2. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
3. Farmer D.G., Kennedy S. RAGE, vascular tone and vascular disease. Pharmacol Ther 2009, 124:185-194.
4. Yan S.F., Ramasamy R., Schmidt A.M. The receptor for advanced glycation end products (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009, 11:e9.
5. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007, 7:711-724.
6. Leclerc E., Fritz G., Vetter S.W., Heizmann C.W. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta 2009, 1793:993-1007.
7. Donato R., Sorci G., Riuzzi F., et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009, 1793:1008-1022.
8. Leśniak W., Słomnicki ŁP, Filipek A. S100A6-new facts and features. Biochem Biophys Res Commun 2009, 390:1087-1092.
9. Engelkamp D., Schäfer B.W., Erne P., Heizmann C.W. S100 alpha, CAPL, and CACY: molecular cloning and expression analysis of three calcium-binding proteins from human heart. Biochemistry 1992, 31:10258-10264.
10. Mandinova A., Atar D., Schäfer B.W., et al. Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium. J Cell Sci 1998, 111:2043-2054.
11. Hsieh H.L., Schäfer B.W., Cox J.A., Heizmann C.W. S100A13 and S100A6 exhibit distinct translocation pathways in endothelial cells. J Cell Sci 2002, 115:3149-3158.
12. Tsoporis J.N., Marks A., Kahn H.J., et al. Inhibition of norepinephrine-induced cardiac hypertrophy in s100beta transgenic mice. J Clin Invest 1998, 102:1609-1616.
13. Tsoporis J.N., Marks A., Haddad A., et al. S100B expression modulates left ventricular remodeling after myocardial infarction in mice. Circulation 2005, 111:598-606.
14. Tsoporis J.N., Izhar S., Leong-Poi H., et al. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res 2010, 106:93-101.
15. Stanton L.W., Garrard L.J., Damm D., et al. Altered patterns of gene expression in response to myocardial infarction. Circ Res 2000, 86:939-945.
16. Tsoporis J.N., Marks A., Haddad A., et al. S100A6 is a negative regulator of the induction of cardiac genes by trophic stimuli in cultured rat myocytes. Exp Cell Res 2005, 303:471-481.
17. Arumugam T., Simeone D.M., Van Golen K., Logsdon C.D. S100P promotes pancreatic cancer growth, survival and invasion. Clin Cancer Res 2005, 11:5356-5364.
18. Kim B., Lee H.J., Choi H.Y., et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007, 67:7431-7438.
19. Austermann J., Nazmi A.R., Muller-Tidow C., Gerke V. Characterization of the Ca2+-regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem 2008, 283:29331-29340.
20. Geroldi D., Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006, 13:1971-1978.
21. Yan X.X., Lu L., Peng W.H., et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2009, 205:544-548.
22. McNair E.D., Wells C.R., Mabood Qureshi A., et al. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 2010, 341:135-138.
23. Fraker T.D., Fihn S.D., Gibbons R.J., et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007, 50:2264-22674.
24. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50:e1-e157.
25. American Diabetes Association Standards of medical care in diabetes-2009. Diabetes Care 2009, 32(Suppl. 1):S13-S61.
26. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
27. Bucciarelli L.G., Kaneko M., Ananthakrishnan R., et al. Receptor for advanced glycation endproducts: key modulator of myocardial ischemic injury. Circulation 2006, 113:1226-1234.
28. Bucciarelli L.G., Ananthakrishnan R., Hwang Y.C., et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 2008, 57:1941-1951.
29. Lanati N., Emanuele E., Brondino N., Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol 2010, 8:86-92.
30. Kalousová M., Hodková M., Kazderová M., et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006, 47:406-411.
31. Hudson B.I., Moon Y.P., Kalea A.Z., et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan study (NOMAS). Atherosclerosis 2011, 216:192-198.
32. Soro-Paavonen A., Watson A.M., Li J., et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008, 57:2461-2469.
33. Sun L., Ishida T., Yasuda T., et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 2009, 82:371-381.
34. Bu D.X., Rai V., Shen X., et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res 2010, 106:1040-1051.
35. Ueno H., Koyama H., Shoji T., et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. Atherosclerosis 2010, 211:431-436.
36. Arumugam T., Simeone D.M., Schmidt A.M., Logsdon C.D. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004, 279:5059-5065.
37. Kim J.K., Jung K.H., Noh J.H., et al. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol 2009, 35:1257-1264.
38. Fuentes M.K., Nigavekar S.S., Arumugam T., et al. RAGE activation by S100P in colon cancer stimulates growth migration, and cell signaling pathways. Dis Colon Rectum 2007, 50:1230-1240.